Search research articles
Contact Us
Filters
Showing results (101-110 of 337) with videos related to
Page
of 34
Sort By:
The Journal of Pediatrics
|
September 3, 2004
Maintaining the nelfinavir trough concentration above 0.8 mg/L improves virologic response in HIV-1-infected children
David M Burger, Alina S Bergshoeff, Ronald De Groot, et al.
Journal of the Pediatric Infectious Diseases Society
|
July 27, 2024
Population Pharmacokinetics of Dolutegravir in African Children: Results From the CHAPAS-4 Trial
Hylke Waalewijn, Roeland E Wasmann, Alasdair Bamford, et al.
Clinical Pharmacology and Therapeutics
|
December 24, 2019
Assessment of Maternal and Fetal Dolutegravir Exposure by Integrating Ex Vivo Placental Perfusion Data and Physiologically-Based Pharmacokinetic Modeling
Jolien J M Freriksen, Stein Schalkwijk, Angela P Colbers, et al.
European Urology
|
September 25, 2018
The Combination of Enzalutamide and Opioids: A Painful Pitfall?
Guillemette E Benoist, Inge M van Oort, David M Burger, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 29, 2020
Drug-induced Liver Injury in a Patient With Coronavirus Disease 2019: Potential Interaction of Remdesivir With P-Glycoprotein Inhibitors
Emiel Leegwater, Anne Strik, Erik B Wilms, et al.
The Journal of Antimicrobial Chemotherapy
|
October 31, 2006
Pharmacokinetics of two generic fixed-dose combinations for HIV-infected children (Pedimune Baby & Pedimune Junior) are similar to the branded products in healthy adults
Rafaëlla F A L'homme, Tim Dijkema, Adilia Warris, et al.
AIDS (London, England)
|
March 13, 2009
Efavirenz dose reduction to 200 mg once daily in a patient treated with rifampicin
Matthijs van Luin, Anne-Marie Brouwer, Andre van der Ven, et al.
AIDS (London, England)
|
November 1, 2021
First pharmacokinetic data of bictegravir in pregnant women living with HIV
Vera E Bukkems, Carmen Hidalgo-Tenorio, Coral Garcia, et al.
Expert Review of Anti-Infective Therapy
|
May 8, 2015
Impact of special patient populations on the pharmacokinetics of echinocandins
Eline W Muilwijk, Vincent J C Lempers, David M Burger, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
April 27, 2005
Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children
Alina S Bergshoeff, Pieter L Fraaij, Jennifer Ndagijimana, et al.
Page
of 34
Search research articles
Search
Showing results (101-110 of 337) with videos related to
Sort By:
Page
of 34
The Journal of Pediatrics
|
September 3, 2004
Maintaining the nelfinavir trough concentration above 0.8 mg/L improves virologic response in HIV-1-infected children
David M Burger, Alina S Bergshoeff, Ronald De Groot, et al.
Journal of the Pediatric Infectious Diseases Society
|
July 27, 2024
Population Pharmacokinetics of Dolutegravir in African Children: Results From the CHAPAS-4 Trial
Hylke Waalewijn, Roeland E Wasmann, Alasdair Bamford, et al.
Clinical Pharmacology and Therapeutics
|
December 24, 2019
Assessment of Maternal and Fetal Dolutegravir Exposure by Integrating Ex Vivo Placental Perfusion Data and Physiologically-Based Pharmacokinetic Modeling
Jolien J M Freriksen, Stein Schalkwijk, Angela P Colbers, et al.
European Urology
|
September 25, 2018
The Combination of Enzalutamide and Opioids: A Painful Pitfall?
Guillemette E Benoist, Inge M van Oort, David M Burger, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 29, 2020
Drug-induced Liver Injury in a Patient With Coronavirus Disease 2019: Potential Interaction of Remdesivir With P-Glycoprotein Inhibitors
Emiel Leegwater, Anne Strik, Erik B Wilms, et al.
The Journal of Antimicrobial Chemotherapy
|
October 31, 2006
Pharmacokinetics of two generic fixed-dose combinations for HIV-infected children (Pedimune Baby & Pedimune Junior) are similar to the branded products in healthy adults
Rafaëlla F A L'homme, Tim Dijkema, Adilia Warris, et al.
AIDS (London, England)
|
March 13, 2009
Efavirenz dose reduction to 200 mg once daily in a patient treated with rifampicin
Matthijs van Luin, Anne-Marie Brouwer, Andre van der Ven, et al.
AIDS (London, England)
|
November 1, 2021
First pharmacokinetic data of bictegravir in pregnant women living with HIV
Vera E Bukkems, Carmen Hidalgo-Tenorio, Coral Garcia, et al.
Expert Review of Anti-Infective Therapy
|
May 8, 2015
Impact of special patient populations on the pharmacokinetics of echinocandins
Eline W Muilwijk, Vincent J C Lempers, David M Burger, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
April 27, 2005
Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children
Alina S Bergshoeff, Pieter L Fraaij, Jennifer Ndagijimana, et al.
Page
of 34